|
US5268454A
(en)
|
1991-02-08 |
1993-12-07 |
La Jolla Pharmaceutical Company |
Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
|
|
KR100361933B1
(ko)
*
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
|
US6410775B1
(en)
*
|
1995-06-07 |
2002-06-25 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
|
US5874409A
(en)
|
1995-06-07 |
1999-02-23 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
|
KR20000016414A
(ko)
*
|
1996-06-06 |
2000-03-25 |
와이즈먼 앤드루 |
Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
|
|
US5817752A
(en)
*
|
1996-06-06 |
1998-10-06 |
La Jolla Pharmaceutical Company |
Cyclic polypeptides comprising a thioether linkage and methods for their preparation
|
|
US8212004B2
(en)
*
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
US6812327B1
(en)
*
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
US6858210B1
(en)
|
1998-06-09 |
2005-02-22 |
La Jolla Pharmaceutical Co. |
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
|
|
IL126447A
(en)
*
|
1998-10-04 |
2004-09-27 |
Vascular Biogenics Ltd |
An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
|
|
US20050197283A1
(en)
*
|
1998-10-04 |
2005-09-08 |
Vascular Biogenics Ltd. |
Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
|
|
US20010010818A1
(en)
*
|
1998-12-09 |
2001-08-02 |
Engle Steven B. |
Methods and formulations for reducing circulating antibodies
|
|
US6458953B1
(en)
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
|
US6399578B1
(en)
|
1998-12-09 |
2002-06-04 |
La Jolla Pharmaceutical Company |
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
|
|
KR20020022691A
(ko)
*
|
1999-06-08 |
2002-03-27 |
와이즈먼 앤드루 |
아미노옥시기를 포함하는 원자가 플랫폼 분자
|
|
AUPQ272699A0
(en)
*
|
1999-09-09 |
1999-09-30 |
Unisearch Limited |
Use of beta2GPI in diagnostic tests for autoimmune diseases
|
|
HK1045944A1
(zh)
*
|
1999-11-28 |
2002-12-20 |
La Jolla Pharmaceutical Company |
基於抗体亲和力的狼疮治疗方法和筛选方法及用於其的组合物
|
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
|
CN1434726A
(zh)
|
2000-06-08 |
2003-08-06 |
拉卓拉药物公司 |
包含高分子量聚环氧乙烷的多价平台分子
|
|
US7879328B2
(en)
*
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
AU2001268427B2
(en)
*
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
WO2002016411A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
CA2418006A1
(en)
*
|
2000-08-18 |
2002-02-28 |
Dyax Corp. |
Binding polypeptides for b lymphocyte stimulator protein (blys)
|
|
US7319012B2
(en)
*
|
2001-05-30 |
2008-01-15 |
Gene Therapy Systems, Inc. |
Protein arrays and methods and systems for producing the same
|
|
CA2451974C
(en)
|
2001-06-21 |
2014-10-14 |
Karen L. Fearon |
Chimeric immunomodulatory compounds and methods of using the same
|
|
US20030114405A1
(en)
*
|
2001-08-13 |
2003-06-19 |
Linnik Matthew D. |
Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
|
|
US7105135B2
(en)
*
|
2001-10-16 |
2006-09-12 |
Lockheed Martin Corporation |
System and method for large scale detection of hazardous materials in the mail or in other objects
|
|
CA2467633C
(en)
*
|
2001-12-03 |
2012-03-27 |
Abgenix, Inc. |
Antibody categorization based on binding characteristics
|
|
WO2003048729A2
(en)
*
|
2001-12-03 |
2003-06-12 |
Abgenix, Inc. |
Discovery of therapeutic products
|
|
AU2002357779A1
(en)
*
|
2001-12-03 |
2003-06-17 |
Abgenix, Inc. |
Identification of high affinity molecules by limited dilution screening
|
|
AU2003237870A1
(en)
*
|
2002-06-07 |
2003-12-22 |
The Brigham & Women's Hospital, Inc. |
Method and composition for inhibing or slowing blood coagulation
|
|
NZ538628A
(en)
|
2002-08-12 |
2008-06-30 |
Dynavax Tech Corp |
Immunomodulatory compositions, methods of making, and methods of use thereof
|
|
AU2003303524A1
(en)
*
|
2002-12-27 |
2004-07-29 |
La Jolla Pharmaceutical Company |
Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
|
|
US20040258683A1
(en)
*
|
2003-03-30 |
2004-12-23 |
Linnik Matthew D. |
Methods of treating and monitoring systemic lupus erythematosus in individuals
|
|
US7771956B2
(en)
*
|
2003-06-30 |
2010-08-10 |
Brigham & Women's Hospital, Inc. |
Method for detecting the presence of a phospholipid
|
|
US9062392B2
(en)
*
|
2003-12-30 |
2015-06-23 |
Intel Corporation |
Methods for isolating a peptide methods for identifying a peptide
|
|
JP2008514187A
(ja)
|
2004-09-01 |
2008-05-08 |
ダイナバックス テクノロジーズ コーポレイション |
先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
|
|
US20080118487A1
(en)
*
|
2004-09-30 |
2008-05-22 |
Orico Limited |
Myostatin Isoform
|
|
DK1853631T3
(en)
*
|
2005-01-24 |
2016-03-29 |
Univ Texas |
Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
|
|
WO2006109312A2
(en)
*
|
2005-04-15 |
2006-10-19 |
Vascular Biogenics Ltd. |
Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
|
|
US9168286B2
(en)
*
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
EA015860B1
(ru)
*
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
US8211649B2
(en)
*
|
2006-03-31 |
2012-07-03 |
Human Genome Sciences, Inc. |
Methods of diagnosing and prognosing hodgkin's lymphoma
|
|
US8309068B2
(en)
*
|
2006-08-03 |
2012-11-13 |
Myostin Therapeutics Pty Ltd. |
Isolated polypeptides and methods of improving muscle strength
|
|
WO2009052148A1
(en)
*
|
2007-10-15 |
2009-04-23 |
California Institute Of Technology |
Functionalized polymers using protected thiols
|
|
CA2703931C
(en)
|
2007-10-26 |
2016-08-16 |
Dynavax Technologies Corporation |
Methods and compositions for inhibition of immune responses and autoimmunity
|
|
WO2010093993A2
(en)
*
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
CN103153346A
(zh)
|
2010-06-16 |
2013-06-12 |
戴纳瓦克斯技术公司 |
使用tlr7和/或tlr9抑制剂的治疗方法
|
|
US9228184B2
(en)
|
2012-09-29 |
2016-01-05 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
CN105353137A
(zh)
*
|
2015-12-10 |
2016-02-24 |
中国农业科学院饲料研究所 |
一种快速检测色素苏丹红的方法
|
|
US12202858B2
(en)
|
2018-10-10 |
2025-01-21 |
Kagoshima University |
Solid-phase carrier including IgG-binding peptide, and IgG separation method
|
|
WO2022197295A1
(en)
*
|
2021-03-17 |
2022-09-22 |
Milliken & Company |
Polymeric colorants with reduced staining
|